Univariate Cox analysis of the three prognostic scores examined with 95%CI intervals for R² calculated by boostrap resampling (in brackets).

<p>Univariate Cox analysis of the three prognostic scores examined with 95%CI intervals for R² calculated by boostrap resampling (in brackets).</p

Prognostic single variables that showed a significant association with overall survival in the univariate Cox analysis.

<p>Prognostic single variables that showed a significant association with overall survival in the univariate Cox analysis.</p

distribution of the phenotypic abnormalities examined according to the median percentage of BM blasts in cytology.

<p>distribution of the phenotypic abnormalities examined according to the median percentage of BM blasts in cytology.</p

Clinical features, PB counts and prognostic scores of the patients.

<p>Clinical features, PB counts and prognostic scores of the patients.</p

Antibodies used in the panel, with clones and sources.

<p>Antibodies used in the panel, with clones and sources.</p

Kaplan-Meier estimates for overall survival of the patients according to WPSS (A), IPSS (B) and IPSS-R (C).

<p>All three scores were able to separate patients with a significantly different survival (p<0.0001).</p

Detection of abnormalities in the granulocytic maturation: plots found in a normal BM on the left and those in a case of RCMD on the right (combination: CD16/CD11b/CD45/CD13).

<p>The granulocytic population was selected on the SSC/CD45 plot (A). The four differentiation stages are distinguishable based on the expression of CD11b, CD16 and CD13 (B–D: orange: promyelocytes; green: myelocytes; purple: metamyelocytes and blue: mature neutrophils). Maturing granulocytes show an abnormal decreased granularity demonstrated by a low SSC (A). Increase of a uniform population with the phenotype CD11b^low/CD13^low/CD16⁻ (promyelocytes) with a gap of maturation between them and myelocytes. Abnormally high expression of CD13 in myelocytes and metamyelocytes (C and D).</p

overall survival of the patients according to the number of CD34⁺/CD13⁺ cells separated in three groups with a different survival by cluster analysis.

<p>Group 1 median: 0.07 (0.02–0.11), group 2 median: 0.46 (0.14–2.36) and group 3: median 5.07 (2.90–27.9) (p<0.0001).</p

Changes in risk category of the patients after reclassification by IPSS-R.

<p>Changes in risk category of the patients after reclassification by IPSS-R.</p

Results of the multivariate analysis considering each of the scores analyzed together with the phenotypic variables presenting an impact on overall survival of the patients.

<p>Results of the multivariate analysis considering each of the scores analyzed together with the phenotypic variables presenting an impact on overall survival of the patients.</p